 The non-active site mutations are considered to affect by other mechanisms, like influencing dimer stability and conformational flexibility.Over 100 single gene point mutations have been described, of which at least 26 are specific to protease inhibitors.Of these, there are about 15 primary or major mutations that are significant enough to change drug activity.